The present disclosure relates to Alkynylphenylbenzamide compounds and the applications thereof. The said Alkynylphenylbenzamide compounds have the structure shown in Formula (I). The compounds can be used as protein kinase inhibitors, which can effectively inhibit the activity of TRK protein kinase and the proliferation, migration and invasion of various tumor cells. At the same time, it has the characteristics of good pharmacokinetics and low toxicity.

##STR00001##

The present disclosure relates to Alkynylphenylbenzamide compounds and the applications thereof. The said Alkynylphenylbenzamide compounds have the structure shown in Formula (I). The compounds can be used as protein kinase inhibitors, which can effectively inhibit the activity of TRK protein kinase and the proliferation, migration and invasion of various tumor cells. At the same time, it has the characteristics of good pharmacokinetics and low toxicity.

##STR00001##

The present invention provides a compound, or a pharmaceutically acceptable salt thereof, of formula (I):

##STR00001##

wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.26, R.sub.27, y, R, M, W, L, V, T, Y, J, K and A are as described herein, therapeutic uses of said compounds, uses of said compounds as research chemicals, a pharmaceutical composition and combinations comprising said compounds, and methods for manufacturing the compounds of the invention.

Provided are an organic electroluminescent material and a device comprising the same. The organic electroluminescent material is a metal complex comprising a ligand L.sub.a having a structure of Formula 1A and a ligand L.sub.b having a structure of Formula 1B. Such new compounds each have a lower evaporation temperature, which is conducive to industrial application of the material and can reduce energy consumption in industrialization. Such metal complexes are used as a light-emitting material in an electroluminescent device. When applied to the electroluminescent device, such metal complexes can provide very excellent device performance, especially an improved device lifetime. Further provided are an organic electroluminescent device comprising the metal complex and a compound composition comprising the metal complex.

Provided are an organic electroluminescent material and a device comprising the same. The organic electroluminescent material is a metal complex comprising a ligand L.sub.a having a structure of Formula 1A and a ligand L.sub.b having a structure of Formula 1B. Such new compounds each have a lower evaporation temperature, which is conducive to industrial application of the material and can reduce energy consumption in industrialization. Such metal complexes are used as a light-emitting material in an electroluminescent device. When applied to the electroluminescent device, such metal complexes can provide very excellent device performance, especially an improved device lifetime. Further provided are an organic electroluminescent device comprising the metal complex and a compound composition comprising the metal complex.

Provided herein are compounds identified as inhibitors of HDAC6 activity having the formula: ##STR00001##
or a pharmaceutically acceptable salt thereof, that can be used to treat various diseases and disorders.

Disclosed are a heterocyclic compound represented by Formula 1 and an organic light emitting device using the same. The heterocyclic compound is used as a material for hole injection layer, hole transport layer, hole injection and transport layer, light emission layer, electron transport layer, or electron injection layer of the organic light emitting device and provides improved efficiency, low driving voltage, and improved lifetime characteristic. ##STR00001##

Disclosed are a heterocyclic compound represented by Formula 1 and an organic light emitting device using the same. The heterocyclic compound is used as a material for hole injection layer, hole transport layer, hole injection and transport layer, light emission layer, electron transport layer, or electron injection layer of the organic light emitting device and provides improved efficiency, low driving voltage, and improved lifetime characteristic. ##STR00001##

The present application provides bifunctional compounds of Formula (X): ##STR00001##
or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, which act as protein degradation inducing moieties for protein kinases. The present application also relates to methods for the targeted degradation of one or more protein kinases through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to one or more protein kinases which can be utilized in the treatment of disorders modulated by protein kinases.

The present application provides bifunctional compounds of Formula (X): ##STR00001##
or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, which act as protein degradation inducing moieties for protein kinases. The present application also relates to methods for the targeted degradation of one or more protein kinases through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to one or more protein kinases which can be utilized in the treatment of disorders modulated by protein kinases.